Fresenius Medical Care (ADR) (FMS)
Runs dialysis clinics and supplies machines, consumables, home therapies, and value-based kidney care.
$22.50
After hours−0.01 (−0.04%)
At close$22.51(+1.31%)
In millions of USD, except per-share figures · converted from EUR at the latest rate
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 5,653 | 5,712 | 5,411 | 5,458 | 5,451 | 5,823 | 5,590 | 5,488 | 5,594 | 5,806 | 5,282 | 5,566 |
| Cost of revenue | 4,245 | 4,167 | 4,067 | 4,123 | 4,139 | 4,368 | 4,234 | 4,097 | 4,172 | 4,216 | 3,931 | 4,066 |
| Gross profit | 1,407 | 1,546 | 1,344 | 1,335 | 1,313 | 1,455 | 1,356 | 1,391 | 1,423 | 1,590 | 1,351 | 1,500 |
| 1,036 | 1,056 | 1,062 | 849 | 783 | 998 | 919 | 939 | 848 | 961 | 921 | 967 | |
| Research & development | 61 | 76 | 55 | 53 | 46 | 57 | 50 | 44 | 43 | 44 | 44 | 45 |
| 909 | 968 | 888 | 883 | 866 | 961 | 860 | 907 | 808 | 899 | 858 | 843 | |
| Selling & marketing | 232 | 0 | 218 | 219 | 229 | 223 | 179 | 211 | 213 | 66 | 169 | 0 |
| General & administrative | 677 | 0 | 670 | 664 | 637 | 739 | 680 | 696 | 595 | 833 | 689 | 843 |
| Other expenses | 66 | 12 | 119 | −87 | −129 | −21 | 9 | −12 | −3 | 18 | 19 | 78 |
| Operating income | 371 | 490 | 282 | 487 | 530 | 457 | 437 | 452 | 575 | 629 | 430 | 534 |
| −102 | −97 | −101 | −97 | −94 | −252 | −150 | −50 | −114 | −46 | −192 | −95 | |
| Interest income | 29 | 31 | 18 | 21 | 19 | 25 | 17 | 25 | 22 | 16 | 17 | 17 |
| Interest expense | 131 | 128 | 119 | 118 | 113 | 116 | 110 | 111 | 107 | 113 | 107 | 112 |
| Other non-operating income | −29 | −31 | −18 | −21 | −19 | 136 | 40 | −60 | 7 | −67 | 86 | 0 |
| Income before tax | 269 | 393 | 181 | 389 | 436 | 205 | 287 | 401 | 461 | 582 | 238 | 439 |
| Income tax expense | 101 | 99 | 45 | 113 | 133 | 70 | 70 | 90 | 86 | 122 | 49 | 103 |
| Net income from continuing operations | 168 | 294 | 135 | 276 | 302 | 135 | 217 | 312 | 375 | 460 | 189 | 336 |
| Net income | 96 | 215 | 81 | 214 | 244 | 77 | 173 | 258 | 315 | 375 | 135 | 250 |
| EPS, basic | $0.11 | $0.25 | $0.07 | $0.18 | $0.22 | $0.07 | $0.30 | $0.45 | $0.54 | $0.65 | $0.25 | $0.47 |
| EPS, diluted | $0.11 | $0.25 | $0.07 | $0.18 | $0.22 | $0.07 | $0.30 | $0.45 | $0.54 | $0.65 | $0.25 | $0.47 |
| Weighted average shares, basic | 880 | 880 | 1,174 | 1,174 | 1,174 | 1,174 | 587 | 587 | 585 | 572 | 550 | 539 |
| Weighted average shares, diluted | 880 | 880 | 1,174 | 1,174 | 1,174 | 1,174 | 587 | 587 | 585 | 572 | 550 | 539 |
| EBITDA | 920 | 1,008 | 887 | 951 | 969 | 867 | 848 | 942 | 977 | 1,123 | 875 | 943 |
| Depreciation & amortization | 520 | 488 | 587 | 443 | 419 | 546 | 452 | 430 | 409 | 428 | 530 | 409 |
| EBIT | 400 | 521 | 300 | 507 | 549 | 321 | 397 | 512 | 568 | 696 | 344 | 534 |